s:**
- Biochemical binding assays measuring PROTAC selectivity for APOE4 vs APOE3
- Mass spectrometry-based degradation kinetics in primary neurons
Background and Rationale
Proteolysis targeting chimeras (PROTACs) represent an innovative therapeutic strategy for selectively degrading disease-associated proteins in neurodegeneration. APOE4, the strongest genetic risk factor for Alzheimer's disease, differs from the protective APOE3 variant by only two amino acids, making selective targeting challenging but therapeutically valuable. This falsification experiment will design and test novel PROTACs engineered to selectively bind and degrade APOE4 while sparing APOE3, addressing the critical need for isoform-specific therapeutic interventions. The study will employ structure-based drug design to create PROTACs with high selectivity ratios, followed by comprehensive biochemical validation using purified proteins and cell-based assays. Primary neuronal cultures and astrocytes will be used to evaluate PROTAC efficacy, selectivity, and potential neurotoxicity using mass spectrometry-based proteomics to monitor protein degradation kinetics.
...s:**
- Biochemical binding assays measuring PROTAC selectivity for APOE4 vs APOE3
- Mass spectrometry-based degradation kinetics in primary neurons
Background and Rationale
Proteolysis targeting chimeras (PROTACs) represent an innovative therapeutic strategy for selectively degrading disease-associated proteins in neurodegeneration. APOE4, the strongest genetic risk factor for Alzheimer's disease, differs from the protective APOE3 variant by only two amino acids, making selective targeting challenging but therapeutically valuable. This falsification experiment will design and test novel PROTACs engineered to selectively bind and degrade APOE4 while sparing APOE3, addressing the critical need for isoform-specific therapeutic interventions. The study will employ structure-based drug design to create PROTACs with high selectivity ratios, followed by comprehensive biochemical validation using purified proteins and cell-based assays. Primary neuronal cultures and astrocytes will be used to evaluate PROTAC efficacy, selectivity, and potential neurotoxicity using mass spectrometry-based proteomics to monitor protein degradation kinetics. Advanced biophysical techniques including surface plasmon resonance and isothermal titration calorimetry will quantify binding affinities and thermodynamic parameters. This research could establish a paradigm for precision medicine approaches in Alzheimer's disease treatment.
This experiment directly tests predictions arising from the following hypotheses:
- Selective APOE4 Degradation via Proteolysis Targeting Chimeras (PROTACs)
- APOE4 Allosteric Rescue via Small Molecule Chaperones
- Targeted APOE4-to-APOE3 Base Editing Therapy
- Competitive APOE4 Domain Stabilization Peptides
- Chaperone-Mediated APOE4 Refolding Enhancement
Experimental Protocol
Phase 1: PROTAC Synthesis and Characterization (Weeks 1-2)• Synthesize APOE4-selective PROTAC compounds using established linker chemistry
• Prepare radiolabeled versions with ¹⁸F or ¹¹C for BBB studies
• Validate compound purity >95% via HPLC-MS
• Confirm structural integrity using ¹H and ¹³C NMR spectroscopy
Phase 2: Biochemical Binding Assays (Weeks 3-4)
• Express and purify recombinant APOE3 and APOE4 proteins (n=3 batches each)
• Perform surface plasmon resonance (SPR) binding assays using Biacore 8K+
• Test PROTAC concentrations: 0.1-100 μM in triplicate
• Measure association/dissociation kinetics at 25°C in HBS-EP+ buffer
• Calculate KD values and selectivity ratios (KD-APOE3/KD-APOE4)
• Include negative controls with scrambled PROTAC sequences
Phase 3: Primary Neuron Culture and Degradation Studies (Weeks 5-7)
• Isolate primary cortical neurons from E18 C57BL/6 mouse embryos
• Culture 2×10⁶ cells per condition in neurobasal medium + B27 supplement
• Transfect neurons with APOE3 or APOE4 expression vectors at DIV 7
• Treat with PROTAC compounds (0.1, 1, 10 μM) for 6, 12, 24, 48h timepoints
• Harvest samples for mass spectrometry analysis using SILAC labeling
• Quantify APOE protein levels via targeted LC-MS/MS with MRM transitions
Phase 4: BBB Penetration Studies (Weeks 8-10)
• Conduct in vivo biodistribution studies in C57BL/6 mice (n=6 per group)
• Inject radiolabeled PROTAC (10 MBq) via tail vein
• Perform PET imaging at 30min, 2h, 6h, and 24h post-injection
• Calculate brain:plasma ratios and BBB penetration coefficients
• Validate with ex vivo gamma counting of brain tissue sections
• Include positive control (²⁰³Pb-labeled transferrin) and vehicle control
Expected Outcomes
APOE4 selectivity: PROTAC demonstrates >10-fold binding selectivity for APOE4 vs APOE3 (KD-APOE4 <100 nM, KD-APOE3 >1 μM)
Dose-dependent degradation: APOE4 protein levels reduced by >70% at 10 μM PROTAC treatment after 24h, while APOE3 levels remain >80% of control
Time-dependent kinetics: Maximal APOE4 degradation occurs between 12-24h post-treatment with DC50 values <1 μM
BBB penetration: Radiolabeled PROTAC achieves brain:plasma ratio >0.3 within 2h, indicating sufficient CNS exposure
Selectivity validation: Mass spectrometry confirms <20% off-target protein degradation in neuronal lysates
Cellular viability: Primary neurons maintain >85% viability after 48h PROTAC treatment as measured by MTT assaySuccess Criteria
• Achieve statistical significance (p<0.05) for APOE4 vs APOE3 binding selectivity with minimum 10-fold difference in KD values
• Demonstrate >50% APOE4 protein degradation with <20% APOE3 degradation at optimal PROTAC concentration (power analysis n≥6)
• Obtain brain:plasma ratio >0.1 for BBB penetration with coefficient of variation <25% across experimental groups
• Maintain primary neuron viability >80% across all treatment conditions with less than 15% variability between replicates
• Achieve mass spectrometry detection sensitivity with signal-to-noise ratio >10 for APOE quantification
• Complete all experimental phases within 10-week timeline with <10% sample loss due to technical failures